Although most of these GPCR-targeted medications have been in use to treat psychiatric disorders since the 1950s (For review [26]), our understanding of their mechanisms in modulating the pathophysiology and improving the clinical symptoms remains limited and equally limited is our understanding of the roles of GPCRs in the etiology of these diseases. Here, LGR6 is linked to psychiatric disorder.